The Age-Related Eye Disease Study 2 (AREDS2) involved about 4,000 patients, the average age of the group being 72, for a five-year time frame (from 2006-2012) to check whether certain nutrients affected the development of eye diseases like cataracts and age-related macular degeneration (AMD). All the patients had early or intermediate AMD.
The researchers split the patients into four groups. One received long-chain polyunsaturated fatty acids (LCPUFAs), one received a lutein and zeaxanthin combination, one was given both, and the other received a placebo. Each participant received cognitive function tests every two years during the study. The eight-part tests were designed to study immediate and delayed recall, attention and memory, and processing speeds. At the end of the study, the researchers noted no significant differences in scores between those that took the supplements and those that took the placebo.
But the researchers also admitted some limitations in the study. They only investigated the potential effects that Omega-3 fish oil pills have and did not include a control group of people who ate foods rich in Omega-3 fatty acids to compare the results. Also, they only looked at individuals with an average age of 72. Chew said that it is uncertain whether Omega-3 fish oil supplements might be beneficial to people in a younger age group. Scientists, however, are curious about other potential benefits and are studying Omega-3 fatty acids to see if they may help relieve symptoms of depression, rheumatoid arthritis and dry eye syndrome.